Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consent Decree Orders FDA Action On Triclosan OTC Monographs

This article was originally published in The Tan Sheet

Executive Summary

A Nov. 21 consent decree sets multiple deadlines over a five-year period to make FDA finalize its OTC topical antimicrobial drug products monograph with respect to triclosan. Under one deadline of note to triclosan product makers, the agency must publish a tentative final monograph for consumer antiseptic hand wash products by Dec. 16, with a final monograph due by Sept. 15, 2016.

You may also be interested in...



Here's The 'Rub' On Antiseptic Washes: FDA Wants Additional Safety, Efficacy Data

FDA says in a proposed rule that it currently does not intend to remove any products containing alcohol or benzalkonium from the market, but asks firms that want to continue marketing the products to submit additional GRAS/GRAE data on the ingredients.

Here's The 'Rub' On Antiseptic Washes: FDA Wants Additional Safety, Efficacy Data

FDA says in a proposed rule that it currently does not intend to remove any products containing alcohol or benzalkonium from the market, but asks firms that want to continue marketing the products to submit additional GRAS/GRAE data on the ingredients.

Cold Indication For Antihistamine Monograph Expected This Year – DNDP Director Michele

FDA this year will publish an antihistamine monograph rule stemming from a partnership with Canada, says Theresa Michele, director of the Division of Nonprescription Drug Products. At a recent CHPA conference, Michele suggested FDA will parlay strong momentum and internal improvements from 2015 into 2016 progress.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel